Where Senior Counsel Navigate Complexity & Drive Business Impact

Equipping Biopharma’s Legal Leaders to Lead with Clarity, Drive AI-Enabled Operational Efficiency & Thrive Amid Relentless Change

The 7th In-House Impact: Biopharma Summit arrives at a time when General Counsels across biopharma are facing a uniquely demanding 2026. FDA expectations remain unsettled, pricing reform continues to evolve, geopolitical tensions are shifting global partnerships and supply chains, and AI is reshaping how legal teams operate. In this environment, GCs must deliver sharper strategic judgment, stronger operational efficiency and clearer enterprise leadership. 

This is the only US forum built exclusively for senior in-house legal leaders across early, growth and commercial stage biopharma organizations. Featuring speakers from companies including Olema Oncology, Caribou BiosciencesEnveda Biosciences, Takeda Oncology, Legend Biotech, Boundless Bio and Sionna Therapeutics, the summit brings together the legal decision makers shaping how scientific assets translate into enterprise value. 

Across two focused days, you will compare approaches to navigating FDA volatility, preparing for pricing reform, designing responsible AI governance, safeguarding IP and trade secrets, strengthening compliance maturity, anticipating crossborder risk and improving deal readiness across partnerships, M&A and IPO preparation. 

Free to attend for inhouse counsel, this is the only place where biopharma GCs and CLOs benchmark with true peers, share candid insight and return with practical strategies they can implement immediately. 

As in-house leaders, we operate at the intersection of strategy, risk and business growth. Hearing how others are navigating similar challenges sharpens my perspective and helps me support thoughtful decision-making across the business.

Sionna Therapeutics

Sionna Therapeutics

Learning from other in-house counsel is so valuable, as we all deal with clients and outside counsel in a specific way. Meeting new people and building my network locally and beyond is priceless”

- Takeda Pharmaceuticals

Takeda Oncology

The 7th In-House Impact: Biopharma Summit looks set to occupy a truly unique and invaluable space in the industry, geared specifically towards General Counsels and their in-house teams within Life Sciences, furthering Legal’s role as a critical business growth enabler

- Roche Diagnostics Corporation

Roche Diagnostics Corporation

Explore the Full Event Guide

  • Complete two-day agenda covering regulatory volatility, AI governance, compliance strategy, and deal readiness
  • 18+ senior legal leaders across biopharma organizations 
  • 15+ strategic panel discussions and fireside chats addressing the biggest challenges facing biopharma GCs in 2026 
  • 8+ hours of dedicated networking, including speed networking and roundtable discussions
  • 1 event that brings together senior in-house counsel from across early-stage, growth-stage, and commercial biopharma 

73310 - 7th In-House Impact Biopharma Summit 2026 (1)

What To Expect

60+

Senior InHouse Legal  Leaders

18+

Confirmed GC, CLO and Senior Legal Speakers

15+

Strategic Panels, Fireside  chats and Roundtable discussions

8+

Hours of Dedicated Networking  Time

2

Days Dedicated to Legal Leadership in 2026

1

Curated Forum Exclusively for Biopharma In-House Counsel

Official Partners

73310 - 7th In-House Impact Biopharma Summit 2026 (1)
Quick Download

Attending Companies Include

Networking Image (4)

Explore the Agenda

Discover the strategies biopharma GCs are using to navigate FDA shifts, pricing reform, AI governance and crossborder risk across two focused days of curated sessions. 

1-768x432

Partner With Us

Showcase your expertise to the in-house community and position your brand as a trusted partner shaping biopharma legal strategy in 2026. 

Speakers Image (2)

Join Biopharma Legal Leaders

Connect with senior inhouse counsel from leading biotechs and pharmaceutical companies during highvalue networking designed for meaningful GCtoGC exchange.